Q1 FY27 Results: Revenue up 18% YoY, PAT flat at Rs 176.5M
WINDLAS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.1 pts less than Nifty Microcap 250 and 7.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Windlas Biotech reported Q1 FY27 results for quarter ended June 30, 2026. Revenue from operations rose 18.1% YoY to Rs 2,481 million from Rs 2,101 million. Profit after tax was nearly flat at Rs 176.53 million versus Rs 176.65 million a year ago, as expenses grew faster. Basic EPS was Rs 8.46. Auditor J.C. Bhalla gave an unmodified limited review. The company completed a Rs 47 crore share buyback in April 2026 and paid a Rs 6.30 per share dividend in July 2026.
Revenue grew 18% YoY but profit was flat due to higher costs. Buyback and dividend are positive for shareholders.